Calnex Solutions Plc (CLX)
London Exchange · UK · prices in GBX · close of 23 Oct 2026
Key indicators
| Last close | GBX 51.00 |
|---|---|
| 52-week range | 40.00 – 82.00 |
| Return, 1 month / 3 months | −10.5% / −13.3% |
| Return, 1 year / 3 years | −4.7% / +18.2% |
| Trend | Below its 200-day average |
| RSI (14) | 27 |
| Volatility (1 year) | 48.0% |
| Worst drawdown (1 year) | -34.3% |
| Average daily value traded | 5.85M GBX |
| Dividend yield | 1.9% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Calnex Solutions designs and makes test and measurement instruments for telecommunications networks, with a focus on timing and synchronisation. Its equipment helps network operators, equipment makers and chip designers check that their systems keep time accurately, which matters for mobile, fixed and data centre networks. The company is based in Scotland and serves customers around the world who build and run communications infrastructure.
Calnex Solutions Plc trades under the code CLX on the London Exchange in UK, with its price quoted in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 6 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Calnex Solutions Plc (CLX) trades on the London Exchange in UK. It last closed at GBX 51.00 on 23 October 2026.
Its price-based Market X-Ray is 43 out of 100 (a weak price profile), ranking 2,443 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 4.7% and over the last three months it fell 13.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 32 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -10.5% | ||
| From 52-week high | -35.0% | ||
| Momentum | 41 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -13.3% | ||
| 6-month return | 0.0% | ||
| 12-month return, skipping the last month | 6.5% | ||
| Stability (higher is calmer) | 35 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 48.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -34.3% | ||
| Liquidity | 69 · Fair | Moderate trading activity. | |
| Average daily value traded | 5.85M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | 59 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 1.9% | ||
| Years with dividends | 6 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −5.6% |
|---|---|
| 1 month | −10.5% |
| 3 months | −13.3% |
| 6 months | −0.0% |
| 1 year | −4.7% |
| 3 years | +18.2% |
| 5 years | −55.7% |
Signals
| 50-day / 200-day average | 56.91 / 56.99 |
|---|---|
| Golden / death cross (60 days) | Death, 0 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.42 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 13 Aug 2026 | GBP 0.0068 |
| 27 Nov 2025 | GBP 0.0031 |
| 24 Jul 2025 | GBP 0.0062 |
| 28 Nov 2024 | GBP 0.0031 |
| 25 Jul 2024 | GBP 0.0062 |
| 30 Nov 2023 | GBP 0.0031 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.